$金斯瑞生物科技(01548)$$bluebird bio(BLUE)$ 今年ASH会议bluebird没做口头报道，灰溜溜的不好意思来啦 Bluebird and Bristol-Myers attempted to steal some of the CAR-T thunder at ASH this year with a release on ide-cel just ahead of the confab. But they’re having trouble with durability when it comes to the excitement level.

Their update on the KarMMa Phase II — a registrational study — touted a 73% ORR on average for all doses used; 31% experienced a complete response and the median progression-free survival data point registered a 8.6 months with a vulnerable 10.6 month average duration of response.

Yes, that is certainly good for a quick approval. But J&J and Legend are overshadowing those results.